H. Bryant

C. Turner, H. Bryant, W. Jee, 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation.

A. Geiser, J. Dodge, J. Henck, 2005, Endocrinology.

Raloxifene and teriparatide (hPTH 1-34) have complementary effects on the osteopenic skeleton of ovariectomized rats

H. Bryant, W. Jee, Y. Ma, 2009, Journal of Bone and Mineral Metabolism.

Selective Estrogen Receptor Modulators

H. Bryant, 2002, Reviews in Endocrine and Metabolic Disorders.

Orally Bioavailable GSK‐3α/β Dual Inhibitor Increases Markers of Cellular Differentiation In Vitro and Bone Mass In Vivo

T. Engler, A. Kriauciunas, H. Bryant, 2006 .

Clomiphene prevents cancellous bone loss from tibia of ovariectomized rats.

R. Turner, H. Bryant, D. Magee, 1997, Endocrinology.

An estrogen receptor basis for raloxifene action in boneProceedings of Xth International Congress on Hormonal Steroids, Quebec, Canada, 17–21 June 1998.

H. Bryant, Masahiko Sato, A. Glasebrook, 1999, The Journal of Steroid Biochemistry and Molecular Biology.

Comment on lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys.

B. Mitlak, D. Cox, H. Bryant, 1998, The Journal of clinical endocrinology and metabolism.

Raloxifene preserves bone strength and bone mass in ovariectomized rats.

C. Turner, M. Sato, H. Bryant, 1994, Endocrinology.

Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: An analysis by DNA microarray

L. Gelbert, A. Maran, S. Lotinun, 2005, Journal of cellular biochemistry.

Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity

J. Dodge, L. Short, H. Bryant, 1997, The Journal of Steroid Biochemistry and Molecular Biology.

Novel and Selective Small Molecule Stimulators of Osteoprotegerin Expression Inhibit Bone Resorption

R. L. Cain, T. Martin, S. Chandrasekhar, 2004, Journal of Pharmacology and Experimental Therapeutics.

Selective estrogen receptor modulators and postmenopausal women's health.

H. Bryant, M. Draper, M. Cox, 1997, Journal of women's health.

Synthesis and pharmacology of 2-alkyl raloxifene analogs

L. Short, H. Bryant, A. Glasebrook, 1996 .

Benzopyran selective estrogen receptor modulators (SERMs): Pharmacological effects and structural correlation with raloxifene

H. Bryant, Masahiko Sato, T. Grese, 1996 .

Environmental estrogens: Effects on cholesterol lowering and bone in the ovariectomized rat

J. Dodge, L. Short, H. Bryant, 1996, The Journal of Steroid Biochemistry and Molecular Biology.

DNA microarray data integration by ortholog gene analysis reveals potential molecular mechanisms of estrogen-dependent growth of human uterine fibroids

A. Geiser, Hui-Rong Qian, H. Bryant, 2007, BMC women's health.

Molecular targets of androgen signaling that characterize skeletal muscle recovery and regeneration

H. Bryant, V. Krishnan, J. Mackrell, 2015, Nuclear receptor signaling.

Raloxifene: A selective estrogen receptor modulator

H. Bryant, Masahiko Sato, A. Glasebrook, 1994, Journal of Bone and Mineral Metabolism.

Stress- and morphine-induced elevations of plasma and tissue cholesterol in mice: reversal by naltrexone.

H. Bryant, C. Kuta, G. K. Yim, 1988, Biochemical pharmacology.

Assessment of endogenous opioid mediation in stress‐induced hypercholesterolemia in the rat.

H. Bryant, G. K. Yim, J. Story, 1988, Psychosomatic medicine.

Follistatin: A Novel Therapeutic for the Improvement of Muscle Regeneration

J. Andrews, A. Datta-Mannan, H. Bryant, 2014, The Journal of Pharmacology and Experimental Therapeutics.

A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats.

A. Geiser, J. Dodge, H. Bryant, 2005, Journal of medicinal chemistry.

Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.

M. Sato, L. Short, H. Bryant, 1997, Journal of medicinal chemistry.

Anti-inflammatory activity of pergolide, a dopamine receptor agonist.

A. Bendele, H. Bryant, S. Spaethe, 1991, The Journal of pharmacology and experimental therapeutics.

Intermittent administration of bovine PTH‐(1–34) increases serum 1,25‐dihydroxyvitamin D concentrations and spinal bone density in senile (23 month) rats

B. Mitlak, D. Paul, R. Neer, 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats

H. Bryant, Masahiko Sato, M. Rippy, 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo.

T. Martin, T. Engler, A. Kriauciunas, 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

A novel class of 5-HT2A receptor antagonists: aryl aminoguanidines.

D. Nelson, H. Bryant, M. Baez, 1996, Life sciences.

Repurposing a novel parathyroid hormone analogue to treat hypoparathyroidism

Catherine Z. Chen, Wei Zheng, G. Tawa, 2018, British journal of pharmacology.

No direct neuronotoxicity by HIV-1 virions or culture fluids from HIV-1-infected T cells or monocytes.

H. Gendelman, J. Orenstein, M. Meltzer, 1992, AIDS research and human retroviruses.

Effects of prolonged ethinyl estradiol treatment on calcium channel binding and in vivo calcium-mediated hemodynamic responses in ovariectomized rats.

C. Vlahos, H. Bryant, M. Cohen, 1997, The Journal of pharmacology and experimental therapeutics.

Dose-response effects of estradiol implants on bone mineral density in ovariectomized ewes.

C. Mallinckrodt, H. Bryant, A. Turner, 1995, Bone.

The effects of raloxifene on tibia histomorphometry in ovariectomized rats.

R. Turner, M. Sato, H. Bryant, 1994, Endocrinology.

Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance.

M. Sato, H. Bryant, Masahiko Sato, 1996, Endocrinology.

Morphine-induced alterations in plasma and tissue cholesterol levels.

H. Bryant, G. K. Yim, J. Story, 1987, Life sciences.

Dual-energy X-ray absorptiometry in sheep: experiences with in vivo and ex vivo studies.

C. Mallinckrodt, H. Bryant, A. Turner, 1995, Bone.

Opioids in immunologic processes

J. Holaday, H. Bryant, 1993 .

17β-hydroxywortmannin: A potent inhibitor of bone resorption and phosphatidylinositol-3-kinase

J. Dodge, B. Norman, C. Vlahos, 1995 .

The selective estrogen receptor modulator, raloxifene: an overview of nonclinical pharmacology and reproductive and developmental testing.

H. Bryant, P. C. Francis, J. Buelke-Sam, 1998, Reproductive toxicology.

Prolactin and prolactin secretagogues reverse immunosuppression in mice treated with cysteamine, glucocorticoids, or cyclosporin-A

J. Holaday, J. Dave, E. Bernton, 1992, Brain, Behavior, and Immunity.

Neuroendocrine Regulation of Immune Function

J. Holaday, E. Bernton, H. Bryant, 1993 .

Brain, Endocrine and Immune Interactions: Implications in Intensive Care

J. Holaday, E. Bernton, H. Bryant, 1989 .

Mandibular bone density in the ovariectomized ewe

M. Edgerton, H. Bryant, A. Turner, 1996 .

Emerging therapies for the prevention or treatment of postmenopausal osteoporosis.

C. Turner, J. Dodge, M. Sato, 1999, Journal of medicinal chemistry.

Immunosuppressive effects of chronic morphine treatment in mice.

J. Holaday, E. Bernton, H. Bryant, 1987, Life sciences.

Role of adrenal cortical activation in the immunosuppressive effects of chronic morphine treatment.

J. Holaday, E. Bernton, H. Bryant, 1991, Endocrinology.

Mechanism of action of estrogens and selective estrogen receptor modulators.

H. Bryant, V. Krishnan, H. Heath, 2000, Vitamins and hormones.

Molecular determinants of tissue selectivity in estrogen receptor modulators.

C. D. Jones, K. Matsumoto, J. Dodge, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Benzothiophene and naphthalene derived constrained SERMs.

A. Geiser, H. Bryant, M. D. Adrian, 2004, Bioorganic & medicinal chemistry letters.

Photochemical synthesis of N-arylbenzophenanthridine selective estrogen receptor modulators (serms).

L. Short, H. Bryant, A. Glasebrook, 2001, Journal of medicinal chemistry.

Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.

H W Cole, M. Sato, L. Short, 1998, Journal of medicinal chemistry.

Selective Estrogen Receptor Modulators: An Alternative to Hormone Replacement Therapy

H. Bryant, W. Dere, 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Osteoporosis Therapy: Mechanistic Antiresorptives

J. Dodge, H. Bryant, 2021, Burger's Medicinal Chemistry and Drug Discovery.

Pharmacologic manipulation of graft versus host induced splenomegaly

H. Bryant, R. E. Roudebush, 1992, Agents and Actions.

Pharmacologic manipulation of a four day murine delayed type hypersensitivity model

H. Bryant, R. E. Roudebush, 2005, Agents and Actions.

Effect of weight manipulation on bone loss due to ovariectomy and the protective effects of estrogen in the rat

A. Bendele, H. Bryant, D. Magee, 1993, Calcified Tissue International.

A selective estrogen receptor modulator for the treatment of hot flushes.

A. Geiser, J. Dodge, H. Bryant, 2006, Journal of medicinal chemistry.

Dissociation of immunosuppression by chlorpromazine and trifluoperazine from pharmacologic activities as dopamine antagonists.

L. Butler, N. Layman, H. Bryant, 1991, International journal of immunopharmacology.

Raloxifene is a Tissue‐Selective Agonist/Antagonist That Functions through the Estrogen Receptor

H W Cole, R. Fuchs-Young, L. Short, 1995, Annals of the New York Academy of Sciences.

Changes in Osteoblast, Chondrocyte, and Adipocyte Lineages Mediate the Bone Anabolic Actions of PTH and Small Molecule GSK‐3 Inhibitor

R. Higgs, T. Engler, E. Dow, 2007, Journal of cellular biochemistry.

Morphine pellet-induced immunomodulation in mice: temporal relationships.

J. Holaday, E. Bernton, H. Bryant, 1988, The Journal of pharmacology and experimental therapeutics.

Mechanism of Action and Preclinical Profile of Raloxifene, a Selective Estrogen Receptor Modulator*

H. Bryant, 2004, Reviews in Endocrine and Metabolic Disorders.

LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.

C. Turner, T. Wang, M. Sato, 1998, The Journal of pharmacology and experimental therapeutics.

Differential responses of estrogen target tissues in rats including bone to clomiphene, enclomiphene, and zuclomiphene.

C. Turner, R. Turner, M. Sato, 1998, Endocrinology.

Expression Profiling of Rat Femur Revealed Suppression of Bone Formation Genes by Treatment with Alendronate and Estrogen but Not Raloxifenes⃞

Shuguang Huang, E. Dow, H. Bryant, 2005, Molecular Pharmacology.

A pharmacological review of raloxifene

H. Bryant, Masahiko Sato, A. Glasebrook, 1996, Journal of Bone and Mineral Metabolism.

Dual‐energy X‐ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats

C. Slemenda, C. Turner, H. Bryant, 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator.

H. Bryant, A. Glasebrook, H. Cole, 1997, The Journal of pharmacology and experimental therapeutics.

Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action.

M. Sporn, S. Dowsett, H. Bryant, 2004, Clinical therapeutics.

Effects of 2% sodium chloride imbibition on various opiate related hyperphagic conditions

H. Bryant, M. Lowy, P. Malven, 1985, Pharmacology Biochemistry and Behavior.

Biochemical effects of estrogen on articular cartilage in ovariectomized sheep.

K A Athanasiou, K. Athanasiou, H. Bryant, 1997, Osteoarthritis and cartilage.

Suppressive effects of morphine pellet implants on in vivo parameters of immune function.

H. Bryant, R. E. Roudebush, 1990, The Journal of pharmacology and experimental therapeutics.

Prolactin and Immune Function

J. Holaday, E. Bernton, H. Bryant, 1991 .

Selective estrogen receptor modulators: pharmacological profile in the rat uterus.

H. Bryant, 1996 .

Conditioned immunosuppression of a murine delayed type hypersensitivity response: Dissociation from corticosterone elevation

H. Bryant, R. E. Roudebush, 1991, Brain, Behavior, and Immunity.

Serotonin-induced paw edema in the rat: pharmacological profile.

H. Bryant, H. Cole, D. Magee, 1995, General pharmacology.

Morphine-induced immunomodulation is not related to serum morphine concentrations.

J. Holaday, E. Bernton, H. Bryant, 1988, European journal of pharmacology.

The Nongenotropic Synthetic Ligand 4-Estren-3α17β-diol Is a High-Affinity Genotropic Androgen Receptor Agonist

J. Dodge, C. Montrose‐Rafizadeh, H. Bryant, 2005, Molecular Pharmacology.

Inhibition of glycinamide ribonucleotide formyltransferase results in selective inhibition of macrophage cytokine secretion in vitro and in vivo efficacy in rat adjuvant arthritis.

G. Sandusky, C. Shih, S. Zuckerman, 2005, Clinical and experimental rheumatology.

Opioid and non-opioid components of insulin-induced feeding

H. Bryant, G. Yim, El'man Si, 1986, Pharmacology Biochemistry and Behavior.

Nocturnal depletion of hypothalamic dynorphin in anorexic walker-256 tumor-bearing rats

H. Bryant, P. Malven, T. Steele, 1988, Pharmacology Biochemistry and Behavior.

Differential inhibition by propranolol of feeding induced in rats by various stimuli

H. Bryant, P. Malven, G. Yim, 1984, Pharmacology Biochemistry and Behavior.

Assessment of maintenance therapy with reduced doses of PTH(1-34) in combination with a raloxifene analogue (LY117018) following anabolic therapy in the ovariectomized rat.

D. Drost, H. Bryant, A. Hodsman, 1999, Bone.

The Addition of a Raloxifene Analog (LY117018) Allows for Reduced PTH(1–34) Dosing During Reversal of Osteopenia in Ovariectomized Rats

D. Drost, H. Bryant, A. Hodsman, 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effect of growth hormone secretagogue LY444711 on IGF‐1, growth hormone, and cortisol levels in beagle dogs after one and seven daily oral doses

J. Dodge, M. Heiman, D. Viswanath, 2000 .

Conversion of the phytoestrogen coumestrol into a selective estrogen receptor modulator (SERM) by attachment of an amine-containing sidechain

L. Short, H. Bryant, A. Glasebrook, 1996 .

Immunomodulatory effects of chronic morphine treatment: pharmacologic and mechanistic studies.

J. Holaday, E. Bernton, H. Bryant, 1990, NIDA research monograph.

Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.

H L Pearce, M. Sporn, N. Suh, 2001, Cancer research.

The Selective Oestrogen Receptor Modulator, LY362321, is Not Neuroprotective in a Rat Model of Transient Focal Ischaemia

J. Dodge, H. Carswell, T. Farr, 2008, Journal of neuroendocrinology.

Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety.

Daniel G Rudmann, A. Geiser, J. Dodge, 2007, Bioorganic & medicinal chemistry letters.

Effects of wortmannin analogs on bone in vitro and in vivo.

J. Dodge, C. Vlahos, W. Matter, 1996, The Journal of pharmacology and experimental therapeutics.

Assessment of dynorphin-A depletion in the anorexia of Walker-256 tumor bearing rats

H. Bryant, P. Malven, G. Yim, 1985, Physiology & Behavior.

Emerging Therapies for the Prevention or Treatment of Postmenopausal Osteoporosis

C. Turner, J. Dodge, H. Bryant, 1999 .

Presence of dynorphin-like immunoreactivity but not opiate binding in Walker-256 tumors.

H. Bryant, G. Isom, P. Malven, 1985, Life sciences.

A nonsecosteroidal vitamin D receptor ligand with improved therapeutic window of bone efficacy over hypercalcemia

S. Iturria, C. Montrose‐Rafizadeh, H. Bryant, 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Central and peripheral temperature changes in sheep following ovariectomy.

C. Mallinckrodt, H. Bryant, E. Lehmer, 2003, Maturitas.

The effect of raloxifene on coronary arteries in aged ovariectomized ewes.

C. Mallinckrodt, H. Bryant, A. Turner, 2000, Journal of veterinary pharmacology and therapeutics.

CNS tissue levels of dynorphin-A immunoreactivity and the anorexia associated with sodium chloride imbibition in the rat

H. Bryant, P. Malven, G. Yim, 1985, Peptides.

Hydrophobic Interactions Improve Selectivity to ERα for Ben-zothiophene SERMs.

M. J. Chalmers, P. Griffin, J. Dodge, 2012, ACS medicinal chemistry letters.

Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulation.

H. Bryant, H U Bryant, 2001, Reviews in endocrine & metabolic disorders.

DNA microarray data integration by ortholog gene analysis reveals potential molecular mechanisms of estrogen-dependent growth of human uterine fibroids

A. Geiser, H. Bryant, J. Onyia, 2007, BMC Women's Health.

Cysteamine produces dose-related bidirectional immunomodulatory effects in mice.

J. Holaday, E. Bernton, H. Bryant, 1989, The Journal of pharmacology and experimental therapeutics.

Dna Microarray Data Integration by Ortholog Gene Analysis Reveals Potential Molecular Mechanisms of Estrogen-dependent Growth of Human Uterine Fibroids

A. Geiser, Hui-Rong Qian, H. Bryant, 2022 .